Skip to main
XNCR

Xencor (XNCR) Stock Forecast & Price Target

Xencor (XNCR) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 14%
Buy 57%
Hold 29%
Sell 0%
Strong Sell 0%

Bulls say

Xencor is a clinical-stage biopharmaceutical company focused on discovering and developing engineered monoclonal antibodies to treat severe and life-threatening diseases with unmet medical needs. Their pipeline includes multiple promising candidates for cancer and autoimmune diseases, and they have a strong history of collaboration and licensing agreements to support their revenue. While there are inherent clinical, competitive, and financial risks, Xencor's diversified set of catalysts and a strong cash position suggest a positive outlook for the company's future growth and success.

Bears say

Xencor is facing significant de-risking with XMAB942's potential success in HS and SYRE's positive read-through on XMAB072's ability to achieve stat-sig improvement in ACR50. With first data from the XENITH-UC trial expected in 2H27 and multiple potential upside drivers from bispecific candidate XmAb412, plamotamab, and XmAb659, Xencor remains well-positioned for success in the biopharmaceutical market. Additionally, the upcoming Phase 1 expansion data update for XmAb819 inccRCC at ESMO in October adds even more potential for success in the near-term.

Xencor (XNCR) has been analyzed by 7 analysts, with a consensus rating of Buy. 14% of analysts recommend a Strong Buy, 57% recommend Buy, 29% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Xencor and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Xencor (XNCR) Forecast

Analysts have given Xencor (XNCR) a Buy based on their latest research and market trends.

According to 7 analysts, Xencor (XNCR) has a Buy consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Xencor (XNCR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.